Clinical Sphingolipids Pathway in Parkinson’s Disease: From GCase to Integrated-Biomarker Discovery

Alterations in the sphingolipid metabolism of Parkinson’s Disease (PD) could be a potential diagnostic feature. Only around 10–15% of PD cases can be diagnosed through genetic alterations, while the remaining population, idiopathic PD (iPD), manifest without validated and specific biomarkers either...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ali Esfandiary, David Isaac Finkelstein, Nicolas Hans Voelcker, David Rudd
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2022-04-01
Col·lecció:	Cells
Matèries:	Parkinson’s disease sphingolipid pathway glucocerebrosidase1 diagnosis
Accés en línia:	https://www.mdpi.com/2073-4409/11/8/1353
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!